$MPLT

Cox Troy purchased $149K of MPLT (indirect holdings)

Cox Troy purchased 15,620 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $9.52 ($0.15M total) on 2026-07-28.

Original reporting
SEC EDGAR · Cox Troy
Published Jul 29, 2026, 1:14 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MPLT
Bullish
low confidence
Mentioned
$MPLT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTBullishLow
01

Why it matters

The newest concrete fact is the disclosed open-market purchase size, price, and post-transaction holdings; it may slightly improve sentiment but does not change fundamentals based on the provided text.

02

Market read

Useful for tracking insider behavior, but the filing alone is unlikely to drive a tradable repricing without additional company-specific catalysts.

03

What to watch

The transaction is described as indirect and not tied to a 10b5-1 plan; without context on prior trades or intent, traders should avoid over-weighting it.

Relevance 5/10Novelty 3/10Timing: as-of the 2026-07-28 Form 4 filing date (reported 2026-07-29)

Background

The article is a primary-source SEC Form 4 insider transaction for MapLight Therapeutics, Inc.

Company-level read

Ticker impact

$MPLTBullishLow confidence
Context

MapLight Therapeutics director Cox Troy filed a Form 4 open-market purchase of 15,620 shares at $9.5200 on 2026-07-28.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a routine insider transaction with no accompanying guidance, deal, or operational update in the text.

Market effects

No sector-level read-across is provided beyond a single insider transaction.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by diversification, liquidity needs, or pre-planned activity, so signal strength may be weak.

Key entities

  • MapLight Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Cox Troy

    Director who purchased 15,620 shares indirectly at $9.5200/share.

Related articles

$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

Med

MapLight Therapeutics stock crashes on Phase II schizophrenia data

MapLight Therapeutics shares fell 71.9% after it reported mixed Phase II schizophrenia trial data, dropping from $35.23 (July 23 close) to $9.90 (July 27 close). The Nasdaq-listed company raised $250m in an Oct 2025 IPO for its ZEPHYR trial. MapLight aims to compete with BMS’s Cobenfy, which GlobalData projects could reach $2.2bn in 2031.

$MPLTMed

MapLight Reports Mixed Results From Phase 2 ZEPHYR Schizophrenia Trial; Shares Fall

MapLight Therapeutics (MPLT) reported mixed topline Phase 2 ZEPHYR schizophrenia results. The 210/3 mg twice-daily dose met the primary PANSS improvement endpoint (effect size 0.37 mITT, p=0.002; 0.50 completers, p=0.002). The 330/6 mg once-daily arm was not statistically significant. Company said cognition improved in impaired patients (effect size 0.51, p=0.041). Shares fell.

$MPLTHighAI 8/10

MapLight Therapeutics stock tumbles 40% on trial results By Investing.com

MapLight Therapeutics (NASDAQ:MPLT) shares fell about 40% after topline Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia. The 210/3 mg twice-daily dose met the primary PANSS endpoint at Week 5 versus placebo, while the 330/6 mg once-daily dose did not. The twice-daily arm also showed significant secondary endpoints; safety was generally tolerable. The company plans an FDA End-of-Phase 2 meeting.

$MPLTMed

MapLight's ML-004 Misses Phase 2 Endpoint But Shows Irritability Signal In Adolescents

MapLight Therapeutics reported topline Phase 2 IRIS results for ML-004 in autism. The study of 161 patients did not meet its primary endpoint: caregiver-reported ABI Social Communication Domain change at week 12 vs placebo. In a prespecified adolescent (12–17) subgroup with baseline irritability, ML-004 improved ABC-I irritability (effect size 1.33, nominal p=0.013) and CGI-I (effect size 1.08, nominal p=0.036). The drug was well tolerated. The company plans an FDA End-of-Phase 2 meeting.